Compare American States Water Company (AWR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Summit Therapeutics Inc — how do they compare? American States Water Company trades at $85.39 (market cap $3.33B), while Summit Therapeutics Inc trades at $14.97 (market cap $12.01B). The key difference: Summit Therapeutics Inc is far larger — about 3.6× American States Water Company's market cap, and American States Water Company pays a 2.37% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AWR | SMMT | |
|---|---|---|
Market Cap | $3.33B | $12.01B |
Sector | Utilities | Health |
52-Week High | $85.05 | $29.32 |
52-Week Low | $70.10 | $13.05 |
Enterprise Value | $4.24B | $11.43B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.
Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
